`Case 1:24-cv-00053-TSK Document 20-3 Filed 07/03/24 Page 1of3 PagelD #: 2764
`
`EXHIBIT 3
`EXHIBIT 3
`
`
`
`Case 1:24-cv-00053-TSK Document 20-3 Filed 07/03/24 Page 2 of 3 PageID #: 2765
`
`From:
`To:
`Cc:
`
`Subject:
`Date:
`Attachments:
`
`Aviv Zalcenstein
`Brett A. Postal; Kayali, Kathryn; Robert Oakes; Laura Fairneny; Neil B. McLaughlin; Terri Mascherin
`Patel, Priyata; Mike Cottler; Shaun Van Horn; John R. Labbe; Argall, Arthur; M710 Team; Jamie.Obrien@steptoe-
`johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept; WFG-aflibercept@willkie.com;
`mhissam@hfdrlaw.com; Carl Shaffer; Andrew Robey; Max Gottlieb; QE - Samsung Bioepis;
`skl@schraderlaw.com; clt@simmermanlaw.com; fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE -
`Formycon Team; MGB-Amgen-ABP938; ABP938; REGENERONPATENT@lists.kellogghansen.com;
`drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell; Kaitlyn McKitrick;
`Eylea.Biosimilars@weil.com; Eylea
`RE: In re aflibercept - May 10 submission m/c
`Wednesday, June 12, 2024 3:18:25 PM
`image001.png
`
`Counsel,
`
`Celltrion, Formycon, and SB have served on Regeneron a non-cumulative set of the categories of
`exhibits to which we agreed in our May 30 email.
`
`Regards,
`
`Aviv Zalcenstein
`he/him/his
`
`
`
`Gemini Law LLP
`40 W 24th Street Suite 6N
`New York, NY 10010
`o +1 917 226 7720
`azalcenstein@geminilaw.com | geminilaw.com
`
`*******************************************************************
`This message was sent from Gemini Law LLP and is intended only for the designated recipient(s). It
`may contain confidential or proprietary information and may be subject to the attorney-client
`privilege or other confidentiality protections. If you are not a designated recipient, you may not review,
`copy or distribute this message. If you receive this in error, please notify the sender by reply e-mail
`and delete this message. Thank you.
`*******************************************************************
`
`
`
`
`From: Aviv Zalcenstein
`Sent: Wednesday, June 5, 2024 8:22 PM
`To: Brett A. Postal <bpostal@rothwellfigg.com>; Kayali, Kathryn <KKayali@wc.com>; Robert Oakes
`<RMO@FR.com>; Laura Fairneny <laurafairneny@quinnemanuel.com>; Neil B. McLaughlin
`
`
`
`Case 1:24-cv-00053-TSK Document 20-3 Filed 07/03/24 Page 3 of 3 PageID #: 2766
`
`<NMcLaughlin@rmmslegal.com>; Terri Mascherin <tmascherin@jenner.com>
`Cc: Patel, Priyata <Priyata.Patel@weil.com>; Mike Cottler <mcottler@geminilaw.com>; Shaun Van
`Horn <vanhorn@fr.com>; John R. Labbe <jlabbe@marshallip.com>; Argall, Arthur
`<aargall@wc.com>; M710 Team <M710Team@rmmslegal.com>; Jamie.Obrien@steptoe-
`johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept <DG-
`Aflibercept@NETORG8512690.onmicrosoft.com>; WFG-aflibercept@willkie.com;
`mhissam@hfdrlaw.com; Carl Shaffer <cshaffer@hfdrlaw.com>; Andrew Robey
`<arobey@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com>; skl@schraderlaw.com; clt@simmermanlaw.com;
`fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE - Formycon Team <SERVICE-
`Formycon_Team@fr.com>; MGB-Amgen-ABP938 <MGB-Amgen-ABP938@marshallip.com>; ABP938
`<ABP938@rothwellfigg.com>; REGENERONPATENT@lists.kellogghansen.com;
`drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell
`<ahardestyodell@bowlesrice.com>; Kaitlyn McKitrick <kmckitrick@bowlesrice.com>;
`Eylea.Biosimilars@weil.com; Eylea <Eylea@wc.com>
`Subject: RE: In re aflibercept - May 10 submission m/c
`
`Counsel,
`
`Celltrion, Formycon, and SB have served on Regeneron the categories of redacted documents to
`which we agreed in our May 30 email. We do not think Regeneron’s proposed protective order
`amendments are appropriate or necessary and do not agree to them, but are available to meet and
`confer on Friday if needed.
`
`Regards,
`
`Aviv Zalcenstein
`he/him/his
`
`
`
`Gemini Law LLP
`40 W 24th Street Suite 6N
`New York, NY 10010
`o +1 917 226 7720
`azalcenstein@geminilaw.com | geminilaw.com
`
`*******************************************************************
`This message was sent from Gemini Law LLP and is intended only for the designated recipient(s). It
`may contain confidential or proprietary information and may be subject to the attorney-client
`privilege or other confidentiality protections. If you are not a designated recipient, you may not review,
`copy or distribute this message. If you receive this in error, please notify the sender by reply e-mail
`and delete this message. Thank you.
`
`